Navigation Links
Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
Date:2/9/2009

LAUSANNE, Switzerland and PARIS, February 9 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Pharmaleads SAS, a science driven drug discovery and early development company, today announced the signature of an exclusive license agreement for the development, registration and commercialisation of a small molecule called Debio 0827 or PL37, about to enter phase I clinical trials. Debio 0827 is the first in a new class of painkillers that could be used in the treatment of chronic pain conditions, primarily in neuropathic pain. Under the terms of the agreement, Debiopharm will make an up-front payment to Pharmaleads, as well as further payments as Pharmaleads reaches predefined development milestones.

"With this agreement we add the new therapeutic area of chronic pain management to the Debiopharm product portfolio. There is currently an unmet medical need for the treatment of chronic pain, which can often not be treated successfully and can seriously affect patients' quality of life. For this reason, we have decided to develop this new therapeutic approach," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group.

"This exclusive licence agreement is very exciting and promising: it will speed up the development of a totally new class of painkillers, hence confirming the validity of our science and chemistry, as well as our capabilities as a drug discovery and early development company," added Thierry Bourbie, Chairman and CEO of Pharmaleads.

Following authorisation from the French Medicine Agency (AFSSAPS), Debio 0827 is about to enter a single ascending dose Phase I, randomised, double-blind, placebo controlled single oral dose escalation study in France, to investigate its safety, tolerability and pharmacokinetics in healthy volunteers.

About N
'/>"/>

SOURCE Pharmaleads
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
2. Japanese Cancer Association and Debiopharm Honour Japanese Research
3. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
4. Debiopharm and EPFL Establish an Oncology Chair
5. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
6. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University
11. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... New York (PRWEB) August 22, 2014 ... one of the interesting and challenging endeavors as ... renders highly impervious properties to the foreign substances. ... as possibility of self medication and minimal use ... low molecular weight drugs and provides specific targeting ...
(Date:8/22/2014)... 2014 The AMA is pleased to ... in Alaska that Alaska Governor Sean Parnell has signed ... defining public use of Unmanned Aircraft Systems and the ... Bill 255states that it is, “An Act relating to ... an unmanned aircraft system.” It defines State of Alaska ...
(Date:8/21/2014)... Aug. 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... first in class collagenase-based products marketed as XIAFLEX ... the U.S. and XIAPEX ® in the ... a randomized, double-blind Phase 2a study of CCH ... fibrosclerotic panniculopathy. The results showed that all three ...
(Date:8/21/2014)... 21, 2014 2014 Deep ... is a professional and in-depth research report ... provides basic Seaweed Fertilizer information, including Seaweed ... structure as well as industry overview. This ... domestic market as well as global industry ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3
... ... -, SOUTH ... of a recent Harris,Interactive(R) survey, showing that an overwhelming majority of Tracleer,patients ... their knowledge of pulmonary arterial hypertension (PAH) and,Tracleer have improved due to ...
... /PRNewswire-FirstCall/ - Helix BioPharma Corp.,(TSX, FSE: "HBP") today announced financial results ... HIGHLIGHTS ---------- - Subsequent to the ... CDN$16.9 million private placement of common shares, subject to ... with Dr. Donald H. Segal remaining the ...
... 17 IRIDEX,Corporation (Nasdaq: IRIX ) today ... Company as Chief Financial Officer effective January 2, ... Officer and Vice President,of Finance for NextHop Technologies, ... as Vice President of Finance and Chief,Financial Officer ...
Cached Biology Technology:Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information 2Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information 3Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information 4Helix BioPharma announces Q1 2008 financial results 2Helix BioPharma announces Q1 2008 financial results 3Helix BioPharma announces Q1 2008 financial results 4Helix BioPharma announces Q1 2008 financial results 5Helix BioPharma announces Q1 2008 financial results 6Helix BioPharma announces Q1 2008 financial results 7Helix BioPharma announces Q1 2008 financial results 8Helix BioPharma announces Q1 2008 financial results 9Helix BioPharma announces Q1 2008 financial results 10Helix BioPharma announces Q1 2008 financial results 11IRIDEX Announces James Mackaness Will Be Chief Financial Officer 2
(Date:8/21/2014)... to ignore, but they are the ultimate source of ... are increasingly dependent on algae, too, to suck up ... to the bottom of the ocean. Now, by using ... have evidence showing that viruses infecting those algae are ... when all else stays essentially the same, and this ...
(Date:8/21/2014)... MELBOURNE, Fla. , Aug. 21, 2014 ...  announced that it has agreed to a ... Orlando,s fastest growing Certified ... make  Gabriel Health Institute  an exclusive member ... a result, Binary Biometrics will improve its ...
(Date:8/21/2014)... from Beth Israel Deaconess Medical Center (BIDMC ) are ... Influential Scientific Minds 2014," a comprehensive list ... resource for science metrics and research performance analysis. ... influential "are performing and publishing work that their peers ... according to a Thomson Reuters statement. Researchers were identified ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... spiders, and other venomous creatures, the "business end," or active ... of a protein that is most likely to undergo rapid ... Gurion University in Israel. Understanding these evolutionary forces can help ... and may also aid in the design of novel synthetic ...
... world, allocating limited health care resources as effectively and ... address that need, systems engineers at the Georgia Institute ... nations improve supply chain decisions related to the distribution ... are also forecasting what health care services would be ...
... Extensive ongoing research on biotic invasions around the world ... research in the United States shows how using improved ... plant species changes the understanding of patterns of species ... was published in the open access journal ...
Cached Biology News:Molding the business end of neurotoxins 2Engineers improve allocation of limited health care resources in resource-poor nations 2Engineers improve allocation of limited health care resources in resource-poor nations 3Human population the primary factor in exotic plant invasions in the United States 2
Request Info...
R26.4C...
... Specifications(L x W x H): 17 ... 5 5/16"18.7 lbsCapacity: 12 slidesTime: Programmable 0 ... Automated denaturation and hybridization steps 40 user ... only, and Fixed temperature) Rapid temperature ramp-up ...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Biology Products: